Mcgill University Health Centre/research Institute Of The Mcgill University Health Centre

This is a compassionate use study for a single patient with Cree Leukoencephalopathy, a rare and fatal brain disease with no approved treatments. The study will provide access to an experimental drug called Fosigotifator (FGT) to see if it can slow or stop the progression of the …

This study is testing whether a diabetes medication called canagliflozin can safely reduce protein in the urine, a sign of kidney damage, in people with advanced kidney disease. It involves two small groups: people with very poor kidney function not yet on dialysis, and people al…

This study provides a single patient with a rare, fatal brain disease access to an experimental drug called fosigotifator. The goal is to see if the drug can slow or stop the breakdown of brain tissue, potentially improving symptoms and quality of life. The patient has no other t…